Allena Pharmaceuticals
Oral enzymes for kidney disease
Newton, Massachusetts, US
Allena Pharmaceuticals develops non-systemic protein therapeutics for metabolic and orphan diseases.
How We Help
Problem Statement
Patients with rare and severe metabolic and kidney disorders suffer from the excess accumulation of metabolites like oxalate and urate, which can cause kidney stones, kidney damage, chronic kidney disease (CKD), and end-stage renal disease.
Core Technology
Oral enzyme therapeutics
Key Differentiators
First-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders
Clinical Focus
Nephrology; Metabolic Disorders
Company Info
- Total Funding
- 40,000,000
- Website
- allenapharma.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Lead candidate reloxaliase in Phase 3 (URIROX-2) with positive Phase 2 data and FDA accelerated approval pathway alignment. ALLN-346 has FDA Fast Track designation for gout-CKD indication. Demonstrated efficacy in reducing urinary oxalate and managing hyperuricemia.
MedStartr Index Score
?What do you think of Allena Pharmaceuticals?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.